Eudragit® microparticles as a possible tool for ophthalmic administration of acyclovir

References

• Al-kassas R. Design and in vitro evaluation of gentamicin-Eudragit® microspheres intended for intra-ocular administration. Journal of Microencapsulation 2004; 21: 71–81
   PubMed Web of Science ®Google Scholar
• Blum MR, Liao SHT, Miranad PD. Overview of acyclovir pharmacokinetic disposition in adults and children. American Journal of Medicine 1982; 73(suppl)186–192
   PubMedGoogle Scholar
• Broadhead J, Rouan SKE, Rhodes CT. The spray-drying of pharmaceuticals. Drug Development and Industrial Pharmacy 1993; 18: 1169–1206
   Google Scholar
• Bucolo C, Maltese A, Puglisi G, Pignatello R. Enhanced ocular anti-inflammatory activity of ibuprofen carried by an Eudragit® RS100 nanoparticle suspension. Ophthalmic Research 2002; 34: 319–323
   PubMed Web of Science ®Google Scholar
• Calvo P, Vila-Jato JL, Alonso MJ. Evaluation of cationic polymer-coated nanocapsules as ocular drug carriers. International Journal of Pharmaceutics 1997; 153: 41–50
   Web of Science ®Google Scholar
• Clarke N, O'Connor K, Ramtoola Z. Infuence of formulation variables on the morphology of biodegradable microparticles prepared by spray-drying. Drug Development and Industrial Pharmacy 1998; 24: 169–174
   PubMed Web of Science ®Google Scholar
• Desai SD, Blanchard J. Pluronic F127-based ocular delivery system containing biodegradable polyisobutylcyanoacrylate nanocapsules of pilocarpine. Drug Delivery 2000; 7: 201–207
   PubMed Web of Science ®Google Scholar
• Douglas JM, Davis LG, Remington ML, Paulsen CA, Perrin EB, Goodman P, Conner JD, Ding D, Corey L. A double-blind, placebo-controlled trial of the effect of chronically administered acyclovir on sperm production in men with frequently recurring genital herpes. Journal of Infection Diseases 1988; 157: 588–559
   PubMed Web of Science ®Google Scholar
• Edwards CA. Anatomical and physiological basis: Physiological factors influencing drug absorption. Colonic drug absorption and metabolism. Marcel Dekker, New York 1993; 1–28
   Google Scholar
• Esposito E, Roncarati R, Cortesi R, Cervellati F, Nastruzzi C. Production of Eudragit® microparticles by spray drying technique: Influence of experimental parameters on morphological and dimensional characteristics. Pharmaceutical Development Technology 2000; 5: 267–278
   PubMed Web of Science ®Google Scholar
• Esposito E, Menegatti E, Cortesi R. Hyaluronan based microspheres as tools for drug delivery: A comparative study. International Journal of Pharmaceutics 2005; 288: 35–49
   PubMed Web of Science ®Google Scholar
• Fruman PA, St Clair MH, Spector T. Acyclovir triphosphate is a suicide inactivator of the herpes simplex virus DNA polymerase. Journal of Biological Chemistry 1984; 259: 9575–9579
   PubMedGoogle Scholar
• Ga De Jalon E, Blanco-Priieto MJ, Ygartua P, Santoyo S. Increased efficacy of acyclovir-loaded microparticles against herpes simplex virus type 1 in cell culture. European Journal of Pharmaceutics and Biopharmaceutics 2003; 56: 183–187
   PubMed Web of Science ®Google Scholar
• Gibson PR, Fixa B, Pekarkova B, Batovsky M, Radford-Smith G, Tibitanzl J, Gabalec L, Florin TH, Greinwald R. Comparison of the efficacy and safety of Eudragit®-L-coated mesalazine tablets with ethylcellulose-coated mesalazine tablets in patients with mild to moderately active ulcerative colitis. Aliment Pharmacological Therapy 2006; 23: 1017–1026
   PubMed Web of Science ®Google Scholar
• Hardy JG. Scintigraphic techniques in studying colonic drug absorption. Colonic drug absorption and metabolism. Marcel Dekker, New York 1993; 77–87
   Google Scholar
• Hill EL, Ellis MN, Nguyen-Dinh P. Antiviral and antiparasitic susceptibility testing. American Society for Microbiology, editors. Manual of Clinical Microbiology. ASM press, Washington DC 1991; 1184–1191
   Google Scholar
• Kotiyan PN, Vavia PR. Eudragit®'s role as crystallization inhibitors in drug-in-adhesive transdermal systems of estradiol. European Journal of Pharmaceutics and Biopharmaceutics 2001; 52: 173–180
   PubMed Web of Science ®Google Scholar
• Lin AY, Augsburger Nouman, LL Muhammad, A Pope D. Study of crystallization of endogenous surfactant in Eudragit® NE30D-free films and its influence on drug-release properties of controlled-release diphenhydramine HCl pellets coated with Eudragit® NE30D. AAPS Pharmsci 3 (2) article 14. 2001, http://www.pharmsci.org/
   Google Scholar
• Lowman AM, Peppas NA. Hydrogels. Encyclopedia of Controlled Drug Delivery. Wiley, New York 1999; 397–418
   Google Scholar
• Merodio M, Irache JM, Valamesh F, Mirshahi M. Ocular disposition and tolerance of ganciclovir-loaded albumin nanoparticles after intravitreal injection in rats. Biomaterial 2002; 23: 1587–1594
   PubMed Web of Science ®Google Scholar
• Modiano P, Salloum E, Gillet-Terver MN, Barbaud A, Georges JC, Thouvenot D, Schmutz JL, Weber M. Acyclovir-resistant chronic cutaneous herpes simplex in Wiskott-Aldrich syndrom. British Journal of Dermatology 1995; 133: 475–478
   PubMed Web of Science ®Google Scholar
• Nastruzzi C, Esposito E, Cortesi R, Gambari R, Menegatti E. Kinetics of bromocriptine release from microsphere: Comparative analysis between different in vitro models. Journal of Microencapsulation 1993; 11: 565–574
   Web of Science ®Google Scholar
• Parris DS, Harrington JE. Herpes simplex virus variants resistant to high concentrations of acyclovir exist in clinical isolates. 1982; 116: 775–779
   Google Scholar
• Pope LE, Marcelletti JF, Katz LR, Lin JY, Katz DH, Parish ML, Spear PG. The anti-herpes simplex virus activity of n-docosanol includes inhibition of the viral entry process. Antiviral Research 1998; 40: 85–94
   PubMed Web of Science ®Google Scholar
• Raffin RP, Jornada DS, Re MI, Pohlmann AR, Guterres SS. Sodium pantoprazole-loaded enteric microparticles prepared by spray drying: Effect of the scale of production and process validation. International Journal of Pharmaceutics 2006; 324(1)10–18
   PubMed Web of Science ®Google Scholar
• Rafiee-Tehram M, Safaii-Nikui N, Peteriet H, Beckert T. Acrylic resins as rate-controlling membranes in novel formulation of a nine-day 17-beta-estradiol transdermal delivery system: In vitro and release modifier effect evaluation. Drug Development and Industrial Pharmacy 2001; 27: 431–437
   PubMedGoogle Scholar
• Reardon JE, Sector T. Herpes simplex virus type I DNA polymerase: Mechanism of inhibition by acyclovir triphosphate. Journal of Biological Chemistry 1989; 264: 7405–7411
   PubMed Web of Science ®Google Scholar
• Reichman RC, Badger GJ, Mertz GJ, Corey L, Richman DD, Connor JD, Redfield D, Savoia MC, Oxman MN, Bryson Y. Treatment of recurrent genital herpes simplex infections with oral acyclovir: A controlled trial. Journal of the American Medical Association 1984; 251: 2103–2107
   PubMed Web of Science ®Google Scholar
• Reid R, Mar EV, Huang ES, Topal MD. Insertion and extension of acyclic, dideoxy, and ara nucleotides by herpesviruses and human polymerises. Journal of Biological Chemistry 1988; 263: 3898–3904
   PubMedGoogle Scholar
• Richards DM, Carmine AA, Brogden RN, Heel RC, Speight TM, Avery GS. Acyclovir. A review of its pharmacodynamic properties and therapeutic efficacy. Drugs 1983; 26: 378–438
   PubMed Web of Science ®Google Scholar
• Sacchetti M, Van Oort MM. Spray-drying and supercritical fluid particle generation technique. Inhalation aerosol: Physical and biological basis for therapy. Marcel Dekker, New York 1996; 337–384
   Google Scholar
• Stahlmann R, Klug S, Lewandowski C, Chahoud I, Bochert G, Merker HJ, Heubert D. Teratogenicity of acyclovir in rats. Infection 1987; 15: 261–262
   PubMed Web of Science ®Google Scholar
• Tucker WE. Pre-clinical toxicology profile of acyclovir: An overview. American Journal of Medicine 1982; 73: 27–30
   PubMed Web of Science ®Google Scholar
• Van Sorge AA, Wijnen PH, Van Delft JL, Carballosa Coré-Bodelier VMW, Van Haeringen NJ. Flurbiprofen, S(+), eyedrops: Formulation, enantiomeric assay, shelflife and pharmacology. Pharmaceutical World Sciences 1999; 21: 91–95
   PubMedGoogle Scholar
• Verma PR, Iyer SS. Transdermal delivery of propranolol using mixed grades of Eudragit®: Design and in vitro and in vivo evaluation. Drug Development and Industrial Pharmacy 2000; 26: 471–476
   PubMed Web of Science ®Google Scholar
• Walro DG, Rosenthal KS. The antiviral xanthate compound D609 inhibits herpes simplex virus type 1 replication and protein phosphorylation. Antiviral Research 1997; 36: 63–72
   PubMedGoogle Scholar
• Washington C. Drug release from microdisperse systems: A critical review. International Journal of Pharmaceutics 1990; 58: 1–12
   Web of Science ®Google Scholar
• Wolff RK, Niven RW. Generation of aerosolized drugs. Journal of Aerosol Medicine 1994; 7: 89–106
   PubMedGoogle Scholar